When the Referee Becomes a Player: What a Government Equity Stake Really Changes
When governments hold equity in the companies they regulate, oversight stops being neutral — it starts having a financial stake in the outcome.
Markets
Markets
Stock markets, macro trends, and geopolitical shifts — explained for the beginning investor.
Markets
Forward Currency Contract: How Companies Buy Certainty They Can’t Actually Own
A forward currency contract lets companies lock in tomorrow’s exchange rate today — but the certainty it buys always has to come from somewhere.
Markets
Ford Tried AI. It Rehired Humans Instead.
Ford lost its AI quality bet, then won by rehiring 350 veteran engineers. The real lesson isn’t about cars — it’s about which kinds of value AI can and can’t absorb.
Markets
Good Players Aren’t Enough. Care Bears Proved It.
Care Bears just quadrupled its revenue without changing a single character — proof that in licensing, and in investing, the system beats the roster every time.
Markets
The Moat Changes Shape. BYD Is Proof.
BYD isn’t winning because it’s cheap. It’s winning because the definition of a moat changed — and almost nobody noticed.
Markets
The Reservoir Was Never the Problem. The Faucet Was.
Korea’s pension fund “needs” to sell $102 billion in stock. The real number — and the real story — is a rule nobody noticed changing in May.
Markets
The Fed Survived the Ruling. Did the Risk?
The Supreme Court just protected Fed independence — on a technicality. Here’s why the ruling changed less than the headlines suggest, and what that means for how you should price political risk.
Markets
Your 401(k) Is Doing the Same Thing
Korea’s Black Tuesday selloff and the target-date fund inside your 401(k) run on the same mechanism — institutions trade weight, not price. Here’s how to spot the next mechanical sell-off before it happens.
Markets
Cheap AI Showed Up. The Bragging Rights Moved.
GLM-5.2 just made frontier AI six times cheaper. Here’s why that doesn’t kill the advantage — it just moves it.
Markets
The Payer Changed, So the Market Followed
GLP-1 drugs didn’t get cheaper — Medicare changed who’s paying. Here’s why that distinction matters more than the price tag.